Calsis Biotherapeutics

Calsis Biotherapeutics is a Cambridge-based biotechnology company focused on developing novel small molecule therapies for inflammatory and respiratory diseases. The company targets the calcium-sensing receptor (CaSR), a protein traditionally associated with calcium homeostasis that has been recently identified as a key driver of airway inflammation. Calsis is developing calcilytics—CaSR antagonists—to treat conditions such as asthma and chronic obstructive pulmonary disease (COPD) by reducing airway hyper-responsiveness. Backed by Medicxi, the company leverages research from Cardiff University to advance its pipeline of preclinical candidates. Calsis aims to provide a new class of anti-inflammatory treatments for patients who do not respond adequately to current standard-of-care therapies.